Matricelf’s autologous regenerative platform is designed to unlock healing in a range of serious medical conditions.
Our initial and primary focus is on treating spinal cord injury (SCI), where there is a clear regulatory path and an urgent unmet need. While SCI is our current priority, the underlying technology holds promise for future expansion into additional indications where functional tissue regeneration could bring meaningful impact.
